Related Experiment Video
Updated: Jul 11, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Leptomeningeal disease in chronic lymphocytic leukemia
C P E Lange1, R E Brouwer, R Brooimans
1Neuro-oncology Unit, Department of Neurology, Medical Centre, The Hague, The Netherlands. chris.lange@ghz.nl
Insights
Leptomeningeal involvement is rare in Chronic Lymphocytic Leukemia (CLL). Early diagnosis and intensive treatment, including chemotherapy and radiation, can lead to complete resolution of neurological symptoms in CLL patients.
Area of Science:
- Hematology
- Neurology
- Oncology
Background:
- Chronic Lymphocytic Leukemia (CLL) is a prevalent lymphoproliferative disorder.
- While often asymptomatic, CLL can progress, leading to lymphadenopathy and significant leukemic burden.
- Leptomeningeal involvement is an uncommon but serious complication of CLL.
Observation:
- This report details a CLL case where leptomeningeal involvement presented as the initial clinical manifestation.
- Neurological symptoms included headache, altered mental status, cranial nerve palsies, and limb weakness.
- Diagnosis was confirmed via cerebrospinal fluid (CSF) cytology and flow cytometry.
Findings:
- Review of this case and 37 literature cases highlights the clinical spectrum of CLL leptomeningeal disease.
- Treatment modalities comprised radiation therapy, intrathecal chemotherapy (cytarabine), and systemic chemotherapy.
- A timely and aggressive therapeutic approach is crucial for managing leptomeningeal disease in CLL.
Implications:
- This study underscores the importance of considering leptomeningeal involvement in CLL patients presenting with neurological deficits.
- Intensive treatment strategies may offer the potential for long-term remission and full recovery from neurological complications.
- Further research into optimal treatment protocols for CLL leptomeningeal disease is warranted.
Abstract:
Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disorder in the western hemisphere, with an annual incidence of 3:100000. Commonly patients are asymptomatic but not rarely disease progression occurs in the setting of lymphadenopathy and extensive leukemic burden. Leptomeningeal involvement in patients with CLL is infrequent, with presenting symptoms of headache (23%), acute or chronic changes in mental status (28%), cranial nerve abnormalities (54%) including optic neuropathy (28%), weakness of lower extremities (23%) and cerebellar signs (18%). In this report, we discuss a CLL patient with leptomeningeal involvement, who presented with neurological symptoms as the first clinical sign, and a diagnosis of leptomeningeal was made based on CSF cytology and flow cytometry. Treatment consisted of radiation therapy and intrathecal chemotherapy with arabinoside-cytosine and systemic chemotherapy. On the basis of this patient-report together with 37 other previously reported cases, the clinical characteristics together with treatment options and outcome of leptomeningeal involvement in CLL are reviewed. Our case together with data from the literature indicate that a timely diagnosis and intensive treatment of leptomeningeal disease of CLL may lead to longstanding and complete resolution of neurological symptoms.
More Related Videos
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Leishmaniasis

